2025-03-01 · bariatric revision, revisional surgery, weight regain, TORe, endoscopic revision, sleeve to bypass, bariatric surgery, GERD after sleeve, surgical, bariatric

Updated 2026-07-28

How common is bariatric surgery revision?

Revision rates depend heavily on the original procedure. Sleeve gastrectomy has the highest long-term revision rate — roughly 10–20% by 10 years in the SLEEVEPASS extension (Salminen 2022, JAMA Surgery) and SM-BOSS (Peterli 2018/2022, JAMA), most often for GERD or inadequate weight loss. Roux-en-Y gastric bypass runs a lower revision rate, roughly 5–15% at 10 years. Adjustable gastric banding is the outlier — long-term band-removal or conversion rates commonly exceed 30–50%, which is a major reason the band has largely been abandoned in the U.S. Overall, revision volume in accredited MBSAQIP centers has grown as the primary-surgery population ages beyond the 5–10 year mark.

How much weight can you lose with a revision?

Revision outcomes are consistently smaller than primary-surgery outcomes and depend on the starting procedure, the reason for revision, and the type of revision. The 2014 SOARD systematic review of revisional bariatric surgery reported average additional total-body-weight loss of about 10–20% over 12–24 months across mixed conversion types, with the fastest change in the first 6–12 months. Sleeve-to-Roux-en-Y-bypass conversions for weight regain typically add 15–20% TWL. Endoscopic revision (TORe) after bypass typically adds a more modest 8–12% TWL at one year. Durability past three years is less well established than for primary surgery.

Is bariatric revision more dangerous than the first surgery?

Yes, meaningfully so. Working in scarred, altered anatomy raises leak, bleeding, stricture, and infection rates. Reported staple-line or anastomotic leak rates for revision run about 2–5% versus roughly 1–2% for primary sleeve or bypass. Operative time is longer, conversion-to-open rates are higher, hospital stays average one to two days longer, and 30-day mortality is roughly doubled from primary surgery — still low in absolute terms at accredited MBSAQIP centers, but not trivial. The complication delta is one of the main reasons 2026 protocols increasingly try GLP-1 medications, behavioral treatment, or endoscopic options before returning to the operating room.

Can I try Ozempic or Wegovy before considering a revision?

For the most common revision indication — weight regain years after a sleeve or bypass — most bariatric programs in 2026 now recommend a formal GLP-1 trial first. Mok and colleagues (2023, JAMA Surgery) reported roughly 12–13% additional total-body-weight loss with semaglutide 2.4 mg in post-bariatric patients at 12 months, and tirzepatide data in this population look at least as strong. A GLP-1 trial has real advantages: it is reversible, avoids the higher complication rate of revision surgery, and — if it works — can defer a second operation indefinitely. Insurance coverage of GLP-1s for post-bariatric regain is inconsistent but improving. See [bariatric surgery vs GLP-1 medications](/weight-loss/bariatric-surgery-vs-glp-1-medications/) for the full framework.

How much does bariatric revision cost in 2026?

Cash-pay pricing at U.S. accredited MBSAQIP centers is typically $20,000–$35,000 for a revision — higher than the $15,000–$25,000 range for a primary sleeve because operative time, ICU risk, and hospital days are all longer. When commercial insurance or Medicare covers the procedure, patients still pay deductible plus coinsurance (commonly $3,000–$8,000 in-network), plus repeat pre-op requirements — nutrition visits, psych evaluation, and often documentation of a supervised GLP-1 or lifestyle attempt. International medical tourism is cheaper on paper (Mexico $6,000–$10,000 for a sleeve-to-bypass conversion) but the follow-up gap and complication-management path are meaningfully riskier for a revision than for a primary.

What if I regained weight after a sleeve — can it be revised?

Yes, and it is the most common revision scenario today. The three main paths are: (1) a GLP-1 trial first (semaglutide or tirzepatide), which now defers or replaces revision surgery in many patients; (2) endoscopic re-sleeve or sleeve-plication (lower morbidity, more modest weight loss); or (3) surgical conversion — typically sleeve to Roux-en-Y gastric bypass for combined regain plus reflux, or sleeve to duodenal switch or SADI-S for high-BMI patients with aggressive metabolic disease. The choice depends on the anatomical cause of regain (a dilated sleeve on imaging shifts toward surgical conversion), current BMI, reflux status, and willingness to accept a higher lifelong nutrient burden.

Is endoscopic revision (TORe) as effective as surgical revision?

Not for weight loss, but the risk trade-off is often worth it. Transoral outlet reduction (TORe) is a scarless endoscopic procedure that uses full-thickness sutures — most commonly with the Overstitch system — to tighten a dilated gastrojejunal outlet after Roux-en-Y gastric bypass. The 2013 Gastroenterology sham-controlled trial showed roughly 3.5% total-body-weight loss at six months versus sham; open-label real-world series report closer to 8–12% TWL at one year. Complication rates are much lower than surgical revision — no leaks, faster recovery, outpatient. Best fits are post-bypass patients with modest to moderate regain, a documented dilated outlet on endoscopy, and no anatomical complication requiring open repair.

Does insurance cover bariatric revision?

Coverage is typically stricter than for primary surgery. Commercial and Medicare plans generally cover revision when there is documented medical necessity: a surgical complication (leak, stricture, fistula), a mechanical failure (dilated pouch or outlet on imaging), a severe complication of the primary procedure (Barrett's esophagus after sleeve, refractory dumping after bypass), or substantial weight regain with recurrent obesity-related comorbidities. Most payers require the original operative report, current imaging or endoscopy, documentation of adherence to the post-op program, and often a documented failed trial of GLP-1 medications or medical weight-loss therapy. Prior authorization denials are common, so plan for an appeals process.

Bariatric Surgery Revision

Bariatric surgery revision is a second procedure done after a first weight-loss surgery for one of three reasons: inadequate weight loss, weight regain, or a complication like a leak, stricture, or severe reflux. Revisions are more technically difficult, carry higher complication rates than primary surgery, and are chosen only when a clear anatomical, metabolic, or complication-driven reason justifies the added risk. This guide walks through what “revision” actually means (and how it differs from a conversion or a reversal), the three reason categories, the common surgical and endoscopic paths, how a GLP-1 trial fits into the 2026 decision framework, the real risk delta versus a first surgery, what it costs, and how to spot predatory revision offers.

Quick stats

• Revision rate after sleeve gastrectomy: roughly 10–20% by 10 years (Salminen 2022, SLEEVEPASS; Peterli 2022, SM-BOSS).
• Revision rate after Roux-en-Y gastric bypass: roughly 5–15% by 10 years.
• Revision or removal rate after adjustable gastric band: commonly 30–50% or higher by 10 years — the main reason the band has largely been abandoned in the U.S.
• Additional total-body-weight loss with revision: roughly 10–20% over 12–24 months across mixed conversion types (SOARD 2014 meta-analysis); 8–12% at one year for endoscopic TORe after bypass.
• Leak rate: ~2–5% after revision vs ~1–2% after primary sleeve or bypass.
• 30-day mortality: roughly doubled compared with primary surgery — still low absolute at accredited MBSAQIP centers.
• Additional weight loss with post-bariatric GLP-1 rescue (semaglutide 2.4 mg): ~12–13% TWL at 12 months in post-bariatric regain (Mok 2023, JAMA Surgery) — often enough to defer revision indefinitely.
• Cash-pay U.S. price: typically $20,000–$35,000 for a revision at an accredited MBSAQIP center.

Who this is for / not for

Good fit if:

• You had a primary bariatric operation and now face a mechanical complication, severe reflux with Barrett’s changes, refractory dumping syndrome or post-bariatric hypoglycemia, a leak, stricture, marginal ulcer, or documented anatomical failure (dilated sleeve, dilated pouch or outlet).
• Your care team has identified a clear anatomical or clinical reason that a first-line non-surgical option cannot address.
• You have completed — or are willing to complete — a documented trial of GLP-1 medication, behavioral therapy, and post-op program re-engagement first.
• You are willing to commit to closer follow-up, more intensive nutrition monitoring, and a higher perioperative-risk conversation.

Not a fit if:

• You are still in the first 12–18 months after your primary surgery and have not fully re-engaged with the post-op program, protein targets, and behavioral support.
• There is no clear surgical or anatomical issue on imaging or endoscopy and the driver is behavioral or medication-responsive.
• You have not tried GLP-1 medications, behavioral therapy, or endoscopic options for a regain-only indication.
• Your overall surgical, anesthesia, or medication-adherence risk is high and the potential gain is modest.

What “revision” actually means

The term “bariatric revision” gets used loosely, but four different procedures live under the umbrella and they are not interchangeable. Sorting them out early is the single biggest step toward matching the right operation to the right problem.

• Revision in the narrow sense means modifying the existing anatomy to correct a mechanical problem — for example, re-sleeving a dilated sleeve, resizing a dilated gastric pouch, or tightening a dilated gastrojejunal outlet (TORe). The original operation stays fundamentally the same shape.
• Conversion means changing one operation into a different one — most commonly sleeve gastrectomy to Roux-en-Y gastric bypass for severe reflux or combined regain, or sleeve to duodenal switch (or SADI-S) for inadequate weight loss at high BMI. Conversion is the most common revision path today.
• Reversal means restoring native anatomy. Full reversal is only realistic for gastric bypass (reconnecting the bypassed segment) and adjustable gastric band (removing the band). Sleeve gastrectomy is not reversible — the removed stomach is discarded and cannot be put back.
• Corrective surgery addresses a specific complication rather than trying to move weight loss — repairing a leak, dilating or resecting a stricture, closing a gastro-gastric fistula, or repairing a paraesophageal hernia. Weight change is not the goal.

Getting this distinction right matters for both consent and expectations. A patient told they are having a “revision” for weight regain is often expecting a wholesale re-do; what they may actually be scheduled for is a conversion to a different operation with a different lifelong nutrient and reflux profile.

The three reason categories

Almost every revision scenario falls into one of three buckets. The right operation depends heavily on which bucket the patient is in.

1. Inadequate weight loss

The working definition most surgeons use is total-body-weight loss under about 20% (or excess-weight loss under about 50%) at 18 months post-op. It is more common after sleeve than after bypass, and more common at higher starting BMIs. The workup looks for both anatomical drivers (dilated sleeve or pouch on imaging) and non-anatomical drivers (nutrition, behavioral, medication effect). The typical revision paths are sleeve-to-Roux-en-Y gastric bypass or sleeve-to-duodenal switch (or SADI-S) for inadequate weight loss at high BMI. These conversions add a meaningful malabsorptive component and produce the largest additional weight-loss numbers of any revision option, at the cost of a higher lifelong micronutrient burden and higher perioperative risk.

2. Weight regain

Regain is different from inadequate loss — the patient reached the expected nadir, then drifted upward. Some regain is normal: 5–10 percentage points from the one-year peak by year five is average, and about 20–30% of patients experience larger regain. The 2026 stepwise response starts with re-engaging the bariatric team, tightening protein and portion tracking, treating any newly-emerged binge-eating pattern, and — increasingly — trialing a GLP-1 medication. Only after that stepwise workup fails does the conversation shift toward endoscopic re-sleeve, TORe, or a formal surgical conversion. Jumping straight to revision surgery for isolated regain, without a GLP-1 trial or behavioral workup, is now considered off-guideline in most U.S. accredited programs.

3. Complications

Complications drive the highest-urgency revisions and the ones where the case for surgery is clearest. The common patterns are severe GERD after sleeve gastrectomy (including erosive esophagitis and Barrett’s changes), pouch or outlet stricture, marginal ulcer after bypass (particularly in smokers and NSAID users), refractory dumping syndrome, malnutrition after bypass or duodenal switch, and gastro-gastric fistula after bypass — the 2018 Mahawar review remains the standard reference for the last of these. The revision here is often a conversion (sleeve to bypass for GERD or Barrett’s) or a corrective procedure (fistula closure, stricture repair, outlet reconstruction) rather than an attempt to move the scale.

Common revision paths

For readers still mapping this against a first operation, sleeve gastrectomy and gastric bypass surgery cover the two most common primaries in detail, and bariatric surgery overview walks the full menu side by side.

Endoscopic vs surgical revision

Endoscopic revision has grown quickly since the 2013 Gastroenterology sham-controlled trial of TORe established its efficacy signal. The main scarless techniques are:

• Transoral outlet reduction (TORe) — full-thickness endoscopic suturing (most commonly with the Apollo Overstitch system) to narrow a dilated gastrojejunal outlet after Roux-en-Y gastric bypass. Anchor evidence: sham-controlled trial (2013), real-world series 8–12% TWL at one year.
• Endoscopic sleeve re-sleeve / sleeve plication — for a dilated sleeve, tighten the tube by placing suture pleats along the greater curvature.
• Sclerotherapy of the gastrojejunal outlet — injection of a sclerosant to induce fibrosis and narrowing; older technique, largely displaced by suturing.

The trade-off is straightforward. Endoscopic revision has meaningfully lower morbidity than surgical conversion — no incisions, outpatient, no leak risk in the surgical sense, faster return to work — but produces less weight loss and has less durable long-term data. Best fits are patients with modest regain, an identifiable anatomical target (a genuinely dilated outlet or sleeve), and either a preference to avoid surgery or a comorbidity that meaningfully raises the operative risk of a formal conversion.

Endoscopic revision is not the right tool for severe reflux with Barrett’s changes, high-BMI inadequate weight loss, dumping syndrome, or a fistula — those still need a surgical answer.

Try GLP-1 medications first?

For weight regain — the single most common trigger for a revision consult — the 2026 answer at most U.S. accredited programs is yes. Semaglutide 2.4 mg and tirzepatide both work in the post-bariatric population, and the trial evidence is now robust enough that skipping this step for a regain-only indication reads as off-guideline.

The anchor data set is Mok and colleagues (2023, JAMA Surgery), a real-world cohort of post-bariatric patients treated with semaglutide 2.4 mg who lost about 12–13% additional total-body weight at 12 months. Tirzepatide data in this population are still maturing but at least match semaglutide. The practical implication is that a well-selected patient who would have been on a revision-surgery track five years ago can now often produce another 20–40 pounds of weight loss without a second operation, while keeping the option of surgical conversion in reserve.

A GLP-1 trial is not the right first move when the indication is a mechanical complication (stricture, fistula, leak), a severe complication of the primary anatomy (Barrett’s after sleeve), or genuinely inadequate weight loss (never reached the expected nadir) at high starting BMI — those situations still need a surgical answer. For the full framework on drugs versus surgery, see bariatric surgery vs GLP-1 medications.

Risks of revision

Working in scarred, altered anatomy is the single fact that shapes the revision risk profile. Compared with a primary sleeve or bypass, the pattern across the SOARD 2014 systematic review, MBSAQIP registry data, and the 2019 ASMBS revision statement is consistent:

• Leak or anastomotic dehiscence: roughly 2–5% vs 1–2% for primary surgery.
• Bleeding: modestly higher.
• Operative time: typically 30–90 minutes longer.
• Conversion-to-open rate: meaningfully higher, particularly for band-removal-plus-conversion done at a single stage.
• Hospital length of stay: typically one to two days longer.
• Stricture rate: higher after revision bypass (marginal ulcer and outlet stricture).
• Nutritional deficiency risk: higher after conversion to a more malabsorptive procedure — B12, iron, thiamine, vitamin D, calcium, folate all need closer monitoring. See the bariatric post-op vitamin and nutrition protocol for the standard supplementation and lab-monitoring stack.
• 30-day mortality: roughly doubled from primary surgery — still low in absolute terms at accredited MBSAQIP centers, but not trivial and part of the informed-consent conversation.

Two practical rules follow. First, staging matters — for band-to-sleeve or band-to-bypass conversions, most experienced centers now stage the operation (remove the band, wait several months, then convert) because the single-stage combined operation has meaningfully higher leak rates. Second, center volume matters more for revisions than for primaries: complication rates drop sharply with surgeon and center revision-specific volume.

Cost & insurance

Revision pricing runs higher than primary bariatric surgery for the same operative reasons — longer OR time, longer stay, higher intensive-care risk. Typical 2026 ranges:

• Cash-pay U.S., accredited MBSAQIP center: roughly $20,000–$35,000 for the revision itself, sometimes higher for a two-stage band-removal-plus-conversion.
• In-network with commercial insurance or Medicare when covered: deductible plus coinsurance typically $3,000–$8,000 for the operation, plus the repeat pre-op requirements — nutrition visits, psychological evaluation, and often a documented supervised weight-loss or GLP-1 trial.
• Medical tourism (Mexico, Colombia, Turkey): sleeve-to-bypass conversion commonly $6,000–$10,000. For a revision specifically, the follow-up gap and complication-management path are a much bigger deal than for a primary — a leak, marginal ulcer, or stricture presenting to a U.S. emergency department three weeks post-op with no operative report available is a difficult scenario. Most U.S. bariatric surgeons will not knowingly take over post-op care for a foreign revision.

Insurance coverage is stricter for revision than for primary surgery. Common approval criteria are: documented complication (leak, stricture, fistula, refractory dumping or Barrett’s changes), mechanical failure on imaging or endoscopy (dilated pouch or outlet), or substantial regain with recurrent obesity-related comorbidities. Documented adherence to the post-op program and often a failed trial of GLP-1 medications are increasingly required. Denials are common — plan for the appeals process, get the original operative report and current imaging in hand early, and pick an in-network MBSAQIP-accredited center. For the full pricing and coverage framework across bariatric procedures, see bariatric surgery cost and insurance coverage.

How to prepare for revision

Once the decision to revise is on the table, the preparation looks a lot like preparing for a primary — with several revision-specific additions.

• Pull your original operative report. The single most useful document for the revision surgeon. If your primary was outside the U.S. or a long time ago, start this request early — turnaround can take weeks.
• Get current imaging or endoscopy. Upper GI series, upper endoscopy, and sometimes CT with contrast define the current anatomy and identify the actual problem (dilated pouch, dilated sleeve, stricture, fistula, Barrett’s).
• Nutritional evaluation. Baseline B12, iron studies, vitamin D 25(OH), calcium, PTH, thiamine, and folate. Correct anything low before surgery — a revision performed on top of chronic malnutrition heals poorly.
• Mental-health evaluation. Rates of eating-disorder history are meaningfully higher in revision candidates than in primary candidates. Screening for binge-eating disorder, night eating syndrome, and a formal history-of-eating-disorders is part of most 2026 protocols. See behavioral therapy for weight loss for the frameworks these programs draw from.
• GLP-1 trial period. For regain-driven revision, most programs now require a documented trial (commonly 6–12 months) of semaglutide 2.4 mg or tirzepatide before surgical conversion.
• Behavioral therapy referral. Especially if the regain pattern points to emotional or binge eating.
• Pick an MBSAQIP-accredited high-volume revision center. Center and surgeon revision-specific volume are the strongest predictors of low complication rates.
• Confirm insurance authorization in writing. Get the specific CPT codes and covered indications on paper before you schedule.

Red flags for predatory revision offers

The revision market has attracted a specific pattern of predatory marketing over the last few years. The concerning offers look like this:

• Revision pitched without a behavioral or GLP-1 trial. A clinic that recommends immediate revision surgery for isolated weight regain, without a documented workup or GLP-1 trial, is not following 2026 practice.
• Aggressive telesales cadence. Same-day booking pressure, “revision special” pricing, discount if you book this week.
• No requirement to see the original operative report. A surgeon willing to revise unknown anatomy is a hard pass.
• No pre-op nutritional or mental-health workup. These are standard-of-care for revision. Skipping them is a marketing choice, not a clinical one.
• No long-term follow-up plan. Revision patients need closer follow-up than primaries, not less.
• Bundled international “medical tourism” revision without U.S. follow-up coverage. A leak or marginal ulcer three weeks post-op is a very different problem when your operative report is in another country.
• “Revision” that turns out to be a re-do of the same operation with no clear anatomical target. A dilated sleeve re-sleeved by a low-volume surgeon has a poor track record; the same anatomy re-created is often the anatomy that failed.

If the pitch looks like the pattern above, get a second opinion at an accredited academic bariatric center before scheduling. The higher risk profile of revision means the cost of getting the choice of surgeon wrong is meaningfully higher than for a primary.

How this compares to other options

• Compared with a first-time procedure like sleeve gastrectomy, revision surgery is more complex because it builds on prior anatomy and has a higher complication rate for the same weight-loss outcome.
• Compared with medical weight loss programs or a formal bariatric surgery vs GLP-1 medications trial, revision addresses surgical anatomy issues that programs and medications cannot correct — but for isolated regain, the non-surgical path is now the first move.
• Compared with endoscopic sleeve gastroplasty and endoscopic TORe, surgical revision produces more weight loss but with meaningfully more morbidity.
• If you are still deciding between primary procedures — or looking at revision to figure out which primary you should have picked — see bariatric surgery types compared for a side-by-side.

Myths vs facts

• Myth: Needing a revision means the first surgery failed. Fact: Some revisions are for complications that had nothing to do with adherence, and some are for the natural anatomical drift most stomachs show over a decade. Framing it as personal failure is both wrong and clinically unhelpful.
• Myth: Revision surgery is just as simple as the original. Fact: Working in scarred anatomy meaningfully raises complication rates and roughly doubles 30-day mortality compared with primary surgery.
• Myth: Insurance always covers revisions. Fact: Coverage is stricter than for primaries, requires more documentation, and denials on the first submission are common.
• Myth: If a sleeve fails, another sleeve is the answer. Fact: The most common revision path after a sleeve is conversion to Roux-en-Y gastric bypass (for reflux or combined regain) or to duodenal switch or SADI-S (for high-BMI inadequate loss), not a re-sleeve.
• Myth: GLP-1 medications don’t work after bariatric surgery. Fact: Post-bariatric patients lose meaningful additional weight on semaglutide 2.4 mg or tirzepatide, often enough to defer revision indefinitely.

Sources at a glance

1. Salminen et al. (2022) — SLEEVEPASS 10-year extension, JAMA Surgery.
2. Peterli et al. (2022) — SM-BOSS 10-year outcomes, JAMA.
3. American Society for Metabolic and Bariatric Surgery — 2019 revisional bariatric surgery position statement.
4. Mahawar et al. (2018) — Gastro-gastric fistula after Roux-en-Y gastric bypass — Obesity Surgery review.
5. Thompson et al. (2013) — Sham-controlled trial of transoral outlet reduction after Roux-en-Y gastric bypass, Gastroenterology.
6. Tran et al. (2014) — Revisional bariatric surgery: a systematic review and meta-analysis, SOARD.
7. Mok et al. (2023) — Semaglutide 2.4 mg for post-bariatric weight regain, JAMA Surgery.
8. American Society for Metabolic and Bariatric Surgery / IFSO (2022) — Updated indications for metabolic and bariatric surgery.